Home / Publications / Pain Research Forum / Papers of the Week / Implications of therapy interruption on monthly migraine days and modified migraine disability assessment in patients treated with erenumab for chronic and episodic migraine: SQUARE study interim results.
Implications of therapy interruption on monthly migraine days and modified migraine disability assessment in patients treated with erenumab for chronic and episodic migraine: SQUARE study interim results.
Authors
Gantenbein AR, Bonvin C, Kamm CP, Schankin CJ, Zecca C, Zieglgänsberger D, Merki-Feld GS, Pohl H, Rudolph N, Ryvlin P, Agosti R, Schäfer E, Meyer I, Kulartz-Schank M, Arzt ME
Abstract
There are limited real-world data in Switzerland examining the impact of erenumab, a fully human IgG2 monoclonal antibody targeting the calcitonin gene-related peptide (CGRP) receptor, on migraine-related quality of life.
This website or its third-party tools use cookies, which are necessary to its functioning and required to achieve the purposes illustrated in the cookie policy. If you want to know more or withdraw your consent to all or some of the cookies, please refer to the IASP Privacy Policy. By closing this banner, you agree to the use of cookies.Agree
